Francesc Valldeoriola1, Francisco Grandas2, Diego Santos-García3, Ignacio Regidor4, María José Catalán5, José Matías Arbelo6, Víctor Puente7, Pablo Mir8,9, Juan Carlos Parra10. 1. Movement Disorders Unit, Neurology Department, Hospital Clínic, Carrer Villarroel, 170, 08036 Barcelona, Spain. 2. Neurology Department, Hospital General Universitario Gregorio Marañón, Calle del Doctor Esquerdo 46, 28007 Madrid, Spain. 3. Neurology Section, Internal Medicine Department, Hospital Arquitecto Marcide, Complejo Hospitalario Universitario de Ferrol (CHUF), Av. Residencia s/n, 15405 Ferrol, A Coruña, Spain. 4. Functional Neurosugery Unit, Hospital Universitario Ramón y Cajal, Carretera Colmenar km 9,100, 28034 Madrid, Spain. 5. Neurology Department, Hospital Clínico San Carlos, Profesor Martín Lagos, S/N, 28040 Madrid, Spain. 6. Neurology Department, Hospital Universitario Insular de Gran Canaria, Avenida Marítima del Sur, s/n, 35016 Las Palmas de Gran Canaria, Spain. 7. Movement Disorders Unit, Neurology Department, Parc de Salut Mar, Institut Municipal d'Investigació Medica Hospital del Mar, Universitat Autònoma de Barcelona, Passeig Marítim, 25-29, 08003 Barcelona, Spain. 8. Movement Disorders Unit, Neurology Department, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Av. Manuel Siurot, s/n, 41013 Sevilla, Spain. 9. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Campus de Cantoblanco, 28049 Madrid, Spain. 10. AbbVie Spain S.L.U. Avenida De Burgos 91, 28050 Madrid, Spain.
Abstract
AIM: To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease. PATIENTS & METHODS: This was an observational, multicenter, cross-sectional, retrospective study. RESULTS: Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily 'off' time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily 'on' time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively. CONCLUSION: This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease.
AIM: To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease. PATIENTS & METHODS: This was an observational, multicenter, cross-sectional, retrospective study. RESULTS: Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily 'off' time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily 'on' time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively. CONCLUSION: This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease.
Authors: Maria José Catalán; Angelo Antonini; Matilde Calopa; Ovidiu Băjenaru; Oriol de Fábregues; Adolfo Mínguez-Castellanos; Per Odin; José Manuel García-Moreno; Stephen W Pedersen; Zvezdan Pirtošek; Jaime Kulisevsky Journal: eNeurologicalSci Date: 2017-07-02
Authors: Oriol De Fabregues; Joan Dot; Monder Abu-Suboh; Jorge Hernández-Vara; Alex Ferré; Odile Romero; Marta Ibarria; José Luis Seoane; Nuria Raguer; Carolina Puiggros; Maria Rosa Gómez; Manuel Quintana; Josep Ramon Armengol; José Alvarez-Sabín Journal: Brain Behav Date: 2017-07-07 Impact factor: 2.708
Authors: Michelle Burack; Jason Aldred; Cindy Zadikoff; Arvydas Vanagunas; Kevin Klos; Bahri Bilir; Hubert H Fernandez; David G Standaert Journal: Mov Disord Clin Pract Date: 2018-06-27